posting velocity //
Loading…
Posting timing (day/hour) is available only when there are at least 5 jobs with a real publish stamp spread across 3 distinct days. This company's source doesn't expose post times, or there isn't enough data yet — showing what we know for sure: how many jobs are open, in which domains, and at which seniority levels.
Based on 19 events over 90 days. Green days had more opens than closes, red vice-versa. The dark line is the 7-day rolling average.
role mix //
The green layer is the current share of active openings by role. The grey dashed layer is the 90-day baseline — gaps between them show where the company is shifting its hiring mix.
seniority pyramid //
Distribution of active openings by seniority. The 'unknown' row groups jobs from sources that don't expose seniority.
geography //
Active openings by region. Click a row to see jobs in that area.
time on market //
Median
44.7 days
25th pct
24.4 days
75th pct
—
Based on 12 closed jobs and 9 still open (right-censored). Curve is Kaplan-Meier; band is the 95% CI.Low event count — the median will stabilise after ~38 more closures. Until then treat the values as indicative.
Window: 180 days back. Don't read the mean — the long tail biases it. Median and percentiles are the honest summary.
Republish rate
0.0%
0 / 12 of closed jobs reposted within 60 days
hiring signal · from our data
From our job data · always current
9 open roles in Israel
Live openings we track — Israel first, plus worldwide when we have them.
Top roles
news feed
<a href="https://news.google.com/rss/articles/CBMiaEFVX3lxTE1RMnNWb1JtUHZ4MHFCdV9EUVBic0F4T2NBUEFjdFlLZ1N3WWZLMXFIaEZZOENUWVpZaEpxY21IMVNrNDZwZml2UW1vMEFFM1lEYThVNEZqQzk0amFPS0xMTVN2TmRBdGc2?oc=5" target="_blank">Teva moves closer to a drug for celiac disease with positive Phase 2 results</a> <font color="#6f6f6f">calcalistech.com</font>
Sep 2, 2026
<p><b>Maris-Tech Announces Financial Results for the Six Months Ended June 30, 2026</b></p>
Sep 2, 2026
Teva reports positive Phase 2a results for Teva-discovered TEV ’408, showing significant prevention of gluten-induced intestinal damage in celiac disease.
Sep 2, 2026
<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE9STlBNdk0zMTVTSWVBUlJpeEZJcGRXV21HX0d4dGhtaUZoT19PXzhOdlhqQkFKZjhXZkkxRVpkUEtUcXYyaHRPaDBDNm9acVUzRDVVeW4yUDRrWHJGQmlXLUsxMU1weEZaWmc?oc=5" target="_blank">Phoenix moves to sell Elron control stake after Arieli defaults on loan terms</a> <font color="#6f6f6f">calcalistech.com</font>
Aug 30, 2026
<p align="center"><i>Sales Nearly Triple Year-Over-Year and Surpass Full-Year 2025 Levels; Gross Margin Improves from a negative 20.6% to 36% with Multiple Orders from Israeli, U.S., and European Customers </i></p>
Aug 26, 2026
Revenues for the second quarter increased by 29.8% year over year, reaching a second quarter record-breaking $782.4 million. Net income attributable to Formula Systems’ shareholders for the second quarter increased by 54.6% year over year, reaching $23.3 million. <pre>Revenues for the second quarter increased by 29.8% year over year, reaching a second quarter record-breaking $782.4 million. Net income attributable to Formula Systems’ shareholders for the second quarter increased by 54.6% year over year, reaching $23.3 million.</pre>
Aug 25, 2026
<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE9rWU9pS21HZkdZbXc2bG1xdnJvd1NJbk9xYnpXSW1aY01rc3ltbFF3RktFUTB1RmlIWTFDcHFLaHE2bGxBZmVpVlczQkhZX2xlM05scG4wVHB0UDBUTWNyMjlxTGt4VE0?oc=5" target="_blank">Israel spends more on education than any developed country. So why are the results so poor?</a> <font color="#6f6f6f">calcalistech.com</font>
Aug 24, 2026
<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTFBHSmg4eUZhM0dtTmotN0UyUmxuMGpMS2ZMUHFDUTRKRmpjSkZBSDc4RWhkYlRzX3ZhQVRya2hSZnJaenBMcjQ5V1VTNU9Sb0ljSUR0T2tTSktGS1VuVUVjQ3ZtUTl1OFk?oc=5" target="_blank">Azrieli’s data center slowdown weighs on results as company bets on renewed growth</a> <font color="#6f6f6f">calcalistech.com</font>
Aug 19, 2026
<p align="center"><em>- Company to host investor conference call today, August 17</em><sup><em>th</em></sup><em>, at 8:30am EDT -</em></p>
Aug 17, 2026
<p align="left"><i>Fort recently signs agreements for the acquisition of Logia USA - fuel integrity solutions for data centers company</i></p>
Aug 14, 2026
<p align="center"><em>FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance</em></p>
Aug 12, 2026
<p align="center"><em>Record </em><em>s</em><em>econd </em><em>q</em><em>uarter 2026 </em><em>r</em><em>evenue</em><em> increased</em> <em>35%</em><em> t</em><em>o $17.</em><em>1 </em><em>m</em><em>illion, </em><em>compared with</em> <em>Q2 2025</em></p>
Aug 12, 2026
<p align="justify">REHOVOT, Israel and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced financial results for the three months and six months ended June 30, 2026.</p>
Aug 12, 2026
<p>MIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced it will issue its press release for its second quarter financial results on Monday August 17, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.</p>
Aug 10, 2026
<p align="center"><strong>Revenue of $123 million, revenue growth of 28%<br /></strong><strong>Year to Date Organic Revenue growth of 24% </strong><sup><strong>(1)<br /></strong></sup><strong>Loss of $10.1 million due to high stock-based compensation expenses. Adjusted Net Income of $6 million<br /></strong><strong>Adjusted EBITDA of $14.1 million </strong><sup><strong>(1) <br /></strong></sup><strong>Reaffirms full year 2026 revenue and Adjusted EBITDA guidance</strong></p>
Aug 10, 2026
<p align="center"><em>New preclinical data presented at European Association for Cancer Research (EACR) 2026 Annual Congress, which further validates the differentiated profile of IM1240's anti-tumor activity, favorable safety and pharmacokinetic profile, and broad therapeutic window</em></p>
Aug 7, 2026
* MIND Receives Nasdaq Notifications <pre>* MIND Receives Nasdaq Notifications</pre>
Aug 6, 2026
* MIND Receives Nasdaq Notifications <pre>* MIND Receives Nasdaq Notifications</pre>
Aug 6, 2026
<p align="center"><em>Revenue Grew 17% to $122.7 </em><em>Million; </em><em>GAAP Operating </em><em>I</em><em>ncome </em><em>was $</em><em>4.7</em><em> Million;</em> <em>Adjusted EBITDA Increased 31% to $15.4 Million</em></p>
Aug 5, 2026
<p align="center"><em>Revenue Grew 17% to $122.7 </em><em>Million; </em><em>GAAP Operating </em><em>I</em><em>ncome </em><em>was $</em><em>4.7</em><em> Million;</em> <em>Adjusted EBITDA Increased 31% to $15.4 Million</em></p>
Aug 5, 2026
Company to Host Conference Call at 8:30am ET <pre>Company to Host Conference Call at 8:30am ET</pre>
Aug 5, 2026
Company to Host Conference Call at 8:30am ET <pre>Company to Host Conference Call at 8:30am ET</pre>
Aug 5, 2026
<p align="center"><strong>$460 million second quarter revenue, 24% year-over-year growth; <br />Guiding third quarter revenue of $520 million, 31% year-over-year growth</strong></p>
Aug 4, 2026
<p align="center"><strong>$460 million second quarter revenue, 24% year-over-year growth; <br />Guiding third quarter revenue of $520 million, 31% year-over-year growth</strong></p>
Aug 4, 2026
<p><strong>NEW YORK</strong> <strong>--</strong> <a href="https://www.globenewswire.com/Tracker?data=Qkwn1uEoXJnpqIRiDQHXE6S3fDIdWr4ZhsWcu7r8UWAN1IT3QBIA3O51_URdk7o1WNPyQiZGPiAFPMHAnPJxAg==" rel="nofollow" target="_blank" title="Wix.com">Wix.com</a> Ltd. (Nasdaq: WIX) (the “Company”), today reported financial results for second quarter 2026. In addition, the Company provided its outlook for the third quarter and reiterated expectations for the full year 2026. Please visit the Wix Investor Relations website at <a href="https://www.globenewswire.com/Tracker?data=xH0gixOs_9cTqIP_aVt-2WVgf8kAsfJeTYpJBxZOO1f8xWyvUMy_A3NKj7xT9s7VuisPd2rOXVRownzURBdTpTPnPusyGqtplxrERxMIivo=" rel="nofollow" target="_blank" title=""><u>https://investors.wix.com</u></a> to view the Q2'26 Shareholder Update and other materials.</p>
Aug 4, 2026